This risk may be related in part to the patient s immune response which can be characterized with respect to the B- and T-cell repertoire.
Patients infected with COVID-19 have an unpredictable risk to worsen and die, making it difficult to decide who can quarantine at home and who should be monitored for respiratory failure as an inpatient. Participants will be contacted by phone or email every 2 months for up to 2 years. Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial. Other participants may give blood samples at NIH or at their local doctor s office or lab. Participants with active infection must be isolated, usually in a hospital. This test will be used to understand research results, not to advise patients. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. Participants will be screened with medical record review. To examine how immune cells respond to COVID-19 infection.Īdults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past.Īlso, healthy donors with no suspected COVID-19 infection
If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. B and T cells are the major components of a person s immune response. Researchers think the risk may be related to how a person s B and T cells respond to the virus. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. People who get infected with COVID-19 have an unpredictable risk to worsen and die.